FOR US HEALTHCARE PROFESSIONALS ONLY
IN ADULTS LIVING WITH SCHIZOPHRENIA
Continue your patient’s treatment plan with the same active ingredient, but fewer doses a year1-5
Evaluated vs placebo and compared to groups of oral antipsychotics
Evaluated in over 2,500 patients across 7 trials
Initiate, maintain, and adjust dosing—and how to transition patients to INVEGA SUSTENNA®
A step-by-step guide for administering INVEGA SUSTENNA®
In a survey of adults with schizophrenia currently taking a long-acting injectable (LAI)
90%
wished they would have started it sooner, now knowing what it’s like to live with schizophrenia.2*
*Based on results from a survey of randomly selected adult patients with schizophrenia (N=200). A subgroup of patients were current LAI users (n=49), and among those users, 90% (n=44/49) agreed strongly, mostly, or somewhat (on a 7-point scale) that they wished they would have started a long-acting injectable treatment sooner after their diagnosis.6
References: 1. INVEGA SUSTENNA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 2. INVEGA TRINZA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 3. INVEGA HAFYERA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 4. INVEGA® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 5. RISPERDAL® [Prescribing Information]. Titusville, NJ: Janssen Pharmaceuticals, Inc. 6. Data on file. Janssen Pharmaceuticals, Inc.